InterMune, Inc. ITMN
today announced that it has reached a definitive agreement with Vidara
Therapeutics International Limited (Vidara) to sell its rights to Actimmune®
(interferon gamma-1b) in a cash transaction valued at $55 million plus a
two-year royalty stream. Vidara is part of an international specialty
pharmaceutical group of companies with operations in Ireland and the United
States.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in